New hope for ph+ ALL: targeted combo shows promise
NCT ID NCT07493161
First seen Jun 26, 2026 · Last updated Jul 24, 2026 · Updated 3 times
Summary
This study is testing a new combination of low-intensity chemotherapy and targeted immunotherapy for people newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Participants will receive a third-generation TKI drug (olverembatinib) and may also get venetoclax and blinatumomab. The goal is to see if adding these drugs helps achieve deeper remission and longer event-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Olverembatinib, Venetoclax, Blinatumomab
- What this could lead to
- If successful, this could offer a more effective and less toxic treatment option for people with newly diagnosed Ph+ ALL, potentially improving long-term survival.
- What could go wrong
- This is an early-phase study with a small number of participants. The added drugs may cause side effects, and it's not yet known if the combination will be better than standard therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PH+ ALL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.